Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence - Wikidata - wikimedia - TriplyDB

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

http://www.wikidata.org/entity/Q34093919

about

Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Impact of heparanase on renal fibrosis Mechanisms of heparanase inhibitors in cancer therapy.Targeting the tumor stroma in hepatocellular carcinoma.The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Targeting heparin and heparan sulfate protein interactions.Heparanase: From basic research to therapeutic applications in cancer and inflammation.Heparanase and macrophage interplay in the onset of liver fibrosis.The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015): Evidence and Consensus on HCC Management.Cell-Extracellular Matrix Mechanobiology: Forceful Tools and Emerging Needs for Basic and Translational Research.Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.

P2860

Q26764892-B4453712-84D5-400C-BC9C-7DB387D52553 Q28083753-F992E980-92FF-4139-8F32-366F0FB9F882 Q30244089-712C0F22-78B4-44C9-8CC0-DEB2E4805C9B Q38366586-18DEDDFA-417A-461F-88A0-FC3D271A3B48 Q38536374-12374E5E-8986-4D4A-A0AA-4839A67B3E6A Q38554626-3D0CE520-59F1-44C5-8EF4-3342A8ECAF0B Q39358916-29FA10DD-61B8-4838-8AD3-1E5B2A25DE1D Q39399937-2636F1C2-0E98-4D2D-A59C-DD3E662564E3 Q42587945-DFB444DC-709F-4309-AA4A-A3001ECA4766 Q43812376-F60720B4-3772-44BC-9BD3-EDF63BA03FB3 Q46027563-9E52EFB2-3BFB-4C4B-8D68-7E09377B71FC Q47310923-F93E3695-9877-48CE-A98D-FFBE69D1BA64 Q48171089-470433EA-1AAE-4AD9-8ED2-11EE7A3BC02D

P2860

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

http://www.wikidata.org/entity/Q34093919

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@ast

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@en

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@nl

type

label

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@ast

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@en

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@nl

prefLabel

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@ast

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@en

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@nl

P1433

Q34093919-732F74F2-C351-4FF0-9673-D240C021D6D4

P1476

Q34093919-AD793CF5-A485-4BCF-92E5-0012A08882DB

P2093

Q34093919-0BF57279-7A28-4676-B862-0F09170AB1C8

Q34093919-12B5AD14-AB7F-47A0-8535-941017817D94

Q34093919-1B97BAD6-A92E-41EF-B316-4649D69B5A3E

Q34093919-46EFA984-BECF-41D9-8241-0D9DA2FE2935

Q34093919-5CC3EB1B-F534-4689-9336-60F6AEC9BBE1

Q34093919-63F0F4A4-2746-467F-B916-A00EED47BB56

Q34093919-694D2B66-2BD5-4139-A386-CC5E2F55497B

Q34093919-71200BFD-062A-466F-AD18-CB61BD57B2CB

Q34093919-859117F3-1515-4E0F-BAB9-C4543B46F206

Q34093919-8C9BA473-734A-49A6-9D8E-C50C349A29A2

P2860

Q34093919-011C00F8-9876-42CE-A1D4-8B38750192FE

Q34093919-26D8B48F-7781-4D9D-89D6-35D62CFA22E6

Q34093919-323CBD00-BFFA-427E-B87F-B58C48D33BE1

Q34093919-414EE0A6-75CE-4250-9683-8E1381F7A1C2

Q34093919-4E205A1F-3223-4A0D-80C4-A406D4BA6218

Q34093919-5FC31EDC-7B8A-4BC3-9014-8A06AB196A62

Q34093919-701B19A9-23E6-4A49-A4DE-0140B624F1A3

Q34093919-7AD358EC-0E02-4F5F-A060-CFE1ECCD5351

Q34093919-97FBE9F0-ED3D-4104-8484-731ED81307FD

Q34093919-99306289-3204-456E-953D-488FBF1E9766

P304

Q34093919-5F929720-CE9C-4053-ADBC-CBA10EC780F2

P31

Q34093919-27B53BB7-50FB-4879-9BDB-3ED87546D16F

P356

Q34093919-FD2B8433-989C-436F-8725-1F020FB8A229

P407

Q34093919-BA5E52F2-F010-4DD8-BD33-2EC1E019A130

P433

Q34093919-01D25D7E-1D36-455C-BAB4-C15BBF5C8DDB

P478

Q34093919-6B5B188E-2829-43CF-A970-F425B7549E6C

P50

Q34093919-6291F51D-D85A-42BC-BEE6-2F099556E270

Q34093919-7C6495CA-B838-4554-B620-D89A83E33121

Q34093919-8E51082C-203B-4ACC-BC23-7CA1F5C51826

Q34093919-D5E62B74-E355-40B0-A5FF-D9180C70436D

P577

Q34093919-4E77E7E5-1D37-4AEC-A545-9D335917765B

P5875

Q34093919-9E8776F5-A8B5-402F-B3C4-976C4E417FDC

P698

Q34093919-08773665-EB36-4282-AA94-1EA2515008FE

P932

Q34093919-EBA2494F-605C-443C-AF8A-B99E10A74A78

P356

WJG.V20.I32.11384

P1433

World Journal of Gastroenterology

P1476

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

@en

P2093

Cheng-Chung Wu

http://www.w3.org/2001/XMLSchema#string

Cheng-Yuan Peng

http://www.w3.org/2001/XMLSchema#string

Deng-Yn Lin

http://www.w3.org/2001/XMLSchema#string

Hong-Zen Yeh

http://www.w3.org/2001/XMLSchema#string

Juliana Chang

http://www.w3.org/2001/XMLSchema#string

King-Tong Mok

http://www.w3.org/2001/XMLSchema#string

Kuan-Lang Lai

http://www.w3.org/2001/XMLSchema#string

Long-Bin Jeng

http://www.w3.org/2001/XMLSchema#string

Mei-Due Yang

http://www.w3.org/2001/XMLSchema#string

Ming-Chin Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance.

Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.

Current approaches to the treatment of early hepatocellular carcinoma.

A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.

P304

11384-11393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V20.I32.11384

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265174829

http://www.w3.org/2001/XMLSchema#string

P698

25170226

http://www.w3.org/2001/XMLSchema#string

P932

4145780

http://www.w3.org/2001/XMLSchema#string